Instil Bio, Inc.

What they do

Instil Bio is a biotechnology company that states it is focused on identifying and advancing innovative therapeutic opportunities. It previously pursued cell therapies including a folate receptor alpha CoStAR TIL cell therapy, and its subsidiary Axion Bio in-licensed the bispecific antibody AXN-2510 from ImmuneOnco in August 2024. Axion Bio announced in January 2026 that it was discontinuing development of AXN-2510, and the ImmuneOnco license and collaboration agreement was terminated that same month. The company now says it is actively seeking to in-license or acquire additional novel therapeutic candidates.

Revenue drivers

• Product sales — None; the 10-K states the company has no products approved for commercialization and has never generated revenue from product sales.
• Historical revenue — Reported annual revenue was $138,000 in 2020 and $0 in 2021, and quarterly revenue was $0 throughout 2021.
• Financing and other income — The company states it has financed operations with its IPO, private placements of convertible preferred stock, rental income, and at-the-market offerings.

Recent performance

For the three and six months ended June 30, 2026, Instil reported net loss per share of $0.63 and $1.25, versus $3.24 and $7.55 a year earlier, with non-GAAP net loss per share of $0.45 and $0.78. Research and development expenses fell to $0.3 million and $0.9 million from $6.7 million and $12.1 million, and in-process research and development was nil versus $10.0 million for both 2025 periods. General and administrative expenses were $5.1 million and $10.5 million, compared to $6.2 million and $15.3 million. Restructuring and impairment charges, net were $0.2 million and $1.2 million versus $0.5 million and $16.6 million. Full-year net losses were $71.4 million in 2025 and $74.1 million in 2024.

Strategy

The company's stated strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates. The August 2026 earnings release says Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates. Following termination of the ImmuneOnco agreement and discontinuation of AXN-2510, the company has no disclosed lead program. Its 10-K describes actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.

Risks

• Going concern — The 10-K states the company identified an indicator of substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $726.5 million as of December 31, 2025.
• No approved products or product revenue — The company has no products approved for commercialization and has never generated revenue from product sales.
• Pipeline uncertainty — AXN-2510 development was discontinued and the ImmuneOnco license terminated in January 2026, leaving the company dependent on in-licensing or acquiring new candidates.
• Competition for assets and talent — The 10-K states many potential competitors have significantly greater financial resources and expertise in identifying acquisition and in-licensing opportunities, research and development, clinical testing and regulatory approvals.

Outlook

Management states that cash, cash equivalents, restricted cash and marketable securities of $69.9 million as of June 30, 2026 are expected to fund the current operating plan beyond 2027. The company says it continues to evaluate potential acquisitions, in-licensing and related opportunities, but has not disclosed a specific therapeutic candidate or transaction. No revenue guidance is provided, and the company reports no products approved for commercialization.